1-2 of 2
Masashi Takano
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway

Kosuke Yoshihara, Tatsuhiko Tsunoda, Daichi Shigemizu, Hiroyuki Fujiwara, Masayuki Hatae, Hisaya Fujiwara, Hideaki Masuzaki, Hidetaka Katabuchi, Yosuke Kawakami, Aikou Okamoto, Takayoshi Nogawa, Noriomi Matsumura, Yasuhiro Udagawa, Tsuyoshi Saito, Hiroaki Itamochi, Masashi Takano, Etsuko Miyagi, Tamotsu Sudo, Kimio Ushijima, Haruko Iwase, Hiroyuki Seki, Yasuhisa Terao, Takayuki Enomoto, Mikio Mikami, Kohei Akazawa, Hitoshi Tsuda, Takuya Moriya, Atsushi Tajima, Ituro Inoue, Kenichi Tanaka
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (5): 1374–1385.
https://doi.org/10.1158/1078-0432.CCR-11-2725
Published: 01 March 2012
View article titled, High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway
Open the PDF for High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway in another window
Includes: Supplementary data
Journal Articles

Gains of 1q21–q22 and 13q12–q14 Are Potential Indicators for Resistance to Cisplatin-based Chemotherapy in Ovarian Cancer Patients

Kazuya Kudoh, Masashi Takano, Tomoyuki Koshikawa, Misako Hirai, Sadao Yoshida, Yoshinori Mano, Kenji Yamamoto, Kenji Ishii, Tsunekazu Kita, Yoshihiro Kikuchi, Ichiro Nagata, Masanao Miwa, Kazuhiko Uchida
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (9): 2526–2531.
Published: 01 September 1999
View article titled, Gains of 1q21–q22 and 13q12–q14 Are Potential Indicators for Resistance to Cisplatin-based Chemotherapy in Ovarian Cancer Patients
Open the PDF for Gains of 1q21–q22 and 13q12–q14 Are Potential Indicators for Resistance to Cisplatin-based Chemotherapy in Ovarian Cancer Patients in another window